Alzheimer's Disease Drug Development Pipeline: March 15, 2026

Therapeutic Landscape Table

Trial Updates

VY1706 and VY7523 — Voyager Therapeutics

Voyager is pursuing two mechanistically distinct tau-targeting approaches in Alzheimer's disease: a tau-silencing gene therapy (VY1706) and an anti-tau antibody (VY7523). Both programs were highlighted in Voyager's Q4 2025 and full-year financial results, released March 9, 2026. ^[2]

VY1706 is an AAV gene therapy designed to silence expression of MAPT, the gene encoding tau, using Voyager's TRACER AAV capsid discovery platform, which identifies novel capsids capable of high brain penetration following intravenous dosing. Following a pre-IND communication with FDA in Q1 2025 and a Type C communication completed in Q1 2026, Voyager is targeting IND submission in Q2 2026 and first-in-human dosing in H2 2026.

VY1706 — IND Timeline: IND submission Q2 2026 / First-in-human H2 2026

Voyager completed a GLP toxicology study in Q1 2026 and a Type C FDA communication confirming a path to IND. IND submission is targeted for Q2 2026, with first-in-human dosing in Alzheimer's disease anticipated H2 2026. If achieved, VY1706 would be among the first tau-silencing gene therapies to enter human trials in AD.

VY7523 is an anti-tau antibody whose MAD clinical trial completed enrollment in Q4 2025. Tau PET imaging data are expected in H2 2026, a readout that will be closely watched given the limited clinical validation of tau-directed antibodies to date.

VY7523 — MAD Trial: Enrollment complete; tau PET data expected H2 2026

VY7523's MAD trial in Alzheimer's disease completed enrollment in Q4 2025. The primary endpoint of interest is tau PET imaging, which would provide the first clinical signal on whether VY7523 achieves target engagement and reduces tau burden in the human CNS. This readout is expected H2 2026 and has the potential to validate or challenge the anti-tau antibody approach.

Voyager ended 2025 with $201.7 million in cash, providing runway into 2028, sufficient to fund both programs through their near-term clinical inflection points. The company is also advancing a non-viral delivery platform (Voyager NeuroShuttle) with a proof-of-concept study using anti-amyloid antibodies demonstrating sustained brain exposure after a single IV dose.

Regulatory Updates

DLB is the second most common form of degenerative dementia after Alzheimer's disease, characterized by the accumulation of α-synuclein Lewy bodies in cortical and subcortical neurons. Up to 75% of DLB patients experience psychosis (including hallucinations and delusions), and many standard antipsychotics are contraindicated due to severe neuroleptic sensitivity reactions. There are currently no approved therapies specifically for DLB psychosis.

Zervimesine (CT1812) — Cognition Therapeutics

Zervimesine is an oral, once-daily investigational sigma-2 receptor modulator that disrupts the binding of toxic Aβ oligomers and α-synuclein to neurons. The Phase 2 SHIMMER study (NCT05225415) enrolled 130 adults with mild-to-moderate DLB, randomized to zervimesine 100mg, 300mg, or placebo for six months. ^[1]

SHIMMER Phase 2 — Neuropsychiatric Outcome: 86% slowing of decline on NPI-12 vs. placebo

Zervimesine demonstrated a particularly robust impact on neuropsychiatric symptoms in SHIMMER, with an 86% slowing of decline on the 12-item Neuropsychiatric Inventory (NPI-12) versus placebo. The drug also showed directionally favorable effects on cognitive fluctuations, memory, movement, and activities of daily living; and critically, did not impair motor function, addressing the core contraindication risk in this population.

On March 2, 2026, Cognition announced receipt of final FDA Type C meeting minutes from a January 21, 2026 meeting, confirming a registrational pathway for zervimesine in DLB psychosis. ^[1] The planned Phase 3 study will focus on neuropsychiatric endpoints (hallucinations, delusions, anxiety, aggression, and agitation) using validated scales. Participants will be randomized to 100mg oral zervimesine or placebo, with an open-label extension available after the study period. Cognition expects to meet with the FDA Division of Psychiatry by midyear 2026 to finalize trial design. A separate Phase 2 START study (NCT05531656) of zervimesine in early Alzheimer's disease is also ongoing with $81 million in NIH/NIA grant support.

Funding / BD Activity

MITI-101 — MindImmune

MindImmune is a private biotechnology company developing immune-focused therapies for neurodegenerative diseases. On March 10, 2026, the Alzheimer's Drug Discovery Foundation (ADDF) awarded MindImmune a $5 million strategic investment to accelerate development of MITI-101, its lead candidate targeting immune pathways driving neuroinflammation and neurodegeneration in Alzheimer's disease. ^[3]

$5M ADDF Strategic Investment: IND-enabling translational studies + early clinical development planning

The award will fund completion of critical translational studies, IND submission preparation, and strategic planning for early clinical development. MITI-101 is designed to modulate immune cell function to intervene upstream in the neuroinflammatory cascade implicated in AD onset and progression, targeting mechanisms that contribute to sustained neuroinflammatory damage rather than downstream amyloid or tau pathology directly. Specific molecular targets and detailed mechanism of action were not disclosed in the announcement.

The ADDF investment carries meaningful quality signal: the Foundation employs rigorous scientific review through its venture-philanthropy model and has historically backed programs that produced clinically validated assets, including PrecivityAD®. ADDF CSO Dr. Howard Fillit's framing of MITI-101 as part of a "broader precision medicine framework" for AD treatment reflects the Foundation's view that immune modulation addresses a driver of neurodegeneration that protein-clearance therapies do not, representing complementary rather than competitive positioning relative to the approved anti-amyloid antibody class.

Investor profile — ADDF: Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is the only public charity solely focused on funding AD drug development. It operates as a venture-philanthropy fund, meaning it applies rigorous investment diligence (scientific advisory board review, milestone-linked disbursement) rather than pure grant-making, and funds both academic labs and private biotech companies. To date, the ADDF has awarded nearly $400 million across 792 drug development, biomarker, and prevention programs in 21 countries. Its portfolio has produced two commercially launched assets: the Amyvid® amyloid PET scan and the PrecivityAD® blood test. The ADDF's typical investment range spans early preclinical through Phase 2, with a preference for programs that address validated AD biology with a clear translational path. Companies seeking ADDF funding should note that the Foundation prioritizes novel mechanisms (not incremental variations on approved classes), expects disclosure of a defined development plan and IND pathway, and uses its scientific staff to conduct independent target and mechanism review prior to award.

Spectris™ — Cognito Therapeutics

Cognito Therapeutics is a late clinical-stage neurotechnology company developing Spectris™, a physician-prescribed at-home device that delivers non-invasive visual and auditory stimulation at 40Hz to evoke coordinated gamma-frequency neural activity across interconnected brain networks. The mechanism is structurally different from every other event in this report: Spectris is an investigational device pursuing FDA authorization rather than a drug or biologic pursuing NDA/BLA approval, and it does not target amyloid, tau, or neuroinflammation through molecular intervention. Instead, it seeks to preserve cognition, daily function, and brain structure by restoring network-level neural activity that is disrupted in AD. On March 5, 2026, Cognito announced the final close of its oversubscribed $105 million Series C. ^[4]

HOPE Pivotal Study (NCT05637801): Fully enrolled — top-line data anticipated H2 2026

The HOPE pivotal study is fully enrolled and top-line data are expected in H2 2026. If positive, Cognito intends to file for FDA authorization and targets commercial launch in 2027. A positive readout would position Spectris as potentially the first at-home, non-pharmacological neuroprotective therapy approved for AD, a commercially distinct category from the infusion-based anti-amyloid antibodies.

The Series C also supports expansion of the Spectris platform into additional neurodegenerative indications through a network of brain health collaboratories, beginning with the WVU Rockefeller Neuroscience Institute. ADDF CSO Dr. Howard Fillit is quoted in the announcement as a supporter, the same individual who backed the MindImmune ADDF grant in the same reporting period, reflecting consistent ADDF interest in non-amyloid, non-tau approaches to AD.

Investor profiles — Cognito $105M Series C: The round was oversubscribed, signaling strong demand ahead of the HOPE readout. Morningside Ventures (lead) is a Hong Kong-based life sciences and technology venture firm founded by Gerald Chan; Morningside has a global biotech portfolio and was among the early institutional investors in Moderna. Gerald Chan's personal quote in the press release signals high-conviction lead sponsorship. IAG Capital Partners and Starbloom Capital are life sciences-focused venture investors. Apollo Health Ventures is the health and longevity investment vehicle associated with the Apollo Global Management ecosystem, a notable participant given Apollo's institutional scale, suggesting crossover interest from the broader longevity/brain health investment category. New Vintage and Benvolio Group are additional life sciences investors. The oversubscription and breadth of investor types (specialist biotech VCs, a major global family office, and a crossover institutional vehicle) signal broad conviction across investor categories in the Spectris data package.

Competitive Intelligence Highlights

1. DLB Psychosis Is Emerging as a Registrational-Grade Indication

Cognition's FDA Type C meeting outcome is a meaningful signal for the broader DLB field. The FDA's acceptance of SHIMMER's neuropsychiatric endpoint data as the basis for a registrational pathway (without requiring an additional Phase 2) implies a regulatory posture that is willing to move quickly in an indication with high unmet need and no approved options. ^[1] For investors tracking the DLB space, this sets a potential precedent: compounds with credible Phase 2 neuropsychiatric data in DLB may be able to pursue registration without a full Phase 2b/3 program. The absence of approved antipsychotics for DLB and the contraindication of many standard agents creates a commercially attractive first-mover opportunity for zervimesine if Phase 3 succeeds.

2. Voyager's Dual Tau Programs Are Setting Up Convergent 2026 Readouts

With VY1706 (gene silencing) approaching first-in-human dosing in H2 2026 and VY7523 (antibody clearance) delivering tau PET data in H2 2026, Voyager will generate two mechanistically distinct clinical data points on tau targeting within the same window. ^[2] Key questions for each: whether TRACER capsid IV delivery achieves sufficient CNS distribution at safe doses in humans, and whether VY7523 produces measurable tau PET reduction, which would be the first clinical biomarker signal on tau antibody target engagement. Together, these readouts will provide the field's most direct near-term evidence on whether tau can be durably reduced in the human brain either by silencing its production or clearing it after synthesis.

3. Tau Is Becoming a Multi-Modality Target

With VY1706 (gene silencing) and VY7523 (antibody clearance) both advancing in 2026, tau is now being pursued through at least two mechanistically distinct strategies simultaneously in clinical-stage programs. This mirrors the amyloid field's trajectory a decade earlier, when both passive immunotherapy (aducanumab, lecanemab) and BACE inhibition were in concurrent development. The H2 2026 tau PET readout for VY7523 will be the most clinically proximate data point for the tau antibody approach, and could inform both Voyager's own development decisions and the broader competitive landscape for tau-directed programs from other companies.

Concluding Remarks

This reporting period captured activity across three distinct event categories (trial updates, a regulatory milestone, and funding/BD activity), with all four events reflecting mechanisms that operate outside the approved amyloid-clearance class.

Trial activity was anchored by Voyager Therapeutics' dual tau programs: VY1706 (gene silencing) and VY7523 (antibody clearance) represent two mechanistically distinct strategies converging on the same target, both approaching key H2 2026 readout windows. Their near-simultaneous data points will provide the field's most direct near-term evidence on whether tau burden can be durably reduced in the human brain. The convergence also reflects a broader strategic reality: tau is becoming a multi-modality target, following the same trajectory that amyloid took a decade earlier when both passive immunotherapy and BACE inhibition were in concurrent development.

Regulatory activity was represented by a positive milestone: Cognition Therapeutics' FDA Type C meeting outcome confirmed a registrational pathway for zervimesine in DLB psychosis based on Phase 2 neuropsychiatric endpoint data alone, without requiring a separate Phase 2b study. This signals a regulatory posture willing to move quickly in indications with high unmet need and no approved options, and sets a potential precedent for other compounds with credible Phase 2 neuropsychiatric data in DLB or related dementias.

Funding and BD activity produced two distinct events that together illustrate the breadth of investor interest in AD. The ADDF's $5M investment in MindImmune reflects growing institutional conviction that immune pathway modulation is a primary AD mechanism, and carries quality signal beyond the dollar amount given the Foundation's track record of backing assets that reached commercial markets. Cognito Therapeutics' oversubscribed $105M Series C, led by Morningside Ventures with Apollo Health Ventures among participants, is the larger and more commercially immediate of the two: HOPE is fully enrolled with data expected H2 2026 and a 2027 commercialization target. Notably, the Cognito raise is for an investigational device, not a drug, illustrating that investor appetite for late-stage AD programs extends beyond the biologic and small-molecule categories.

The period reflects a broader maturation of the neurodegeneration pipeline: all five events involve mechanisms operating outside the approved amyloid-clearance class: tau gene silencing, tau antibody clearance, sigma-2 receptor modulation, immune pathway modulation, and non-invasive neurostimulation. This diversification of both mechanism and modality is the defining trend in the current AD development landscape.

Methodology and Sources

This report covers the period March 1, 2026 through March 15, 2026. Events were identified through systematic monitoring of SEC EDGAR 8-K filings, company press releases, and corporate financial disclosures from publicly traded clinical-stage biotechnology and pharmaceutical companies with active programs in Alzheimer's disease and related dementias. Source documents were reviewed in full; only events where the primary focus was a discrete clinical, regulatory, or business milestone were included. General pipeline updates without a specific triggering event were excluded.

The report covers five events across four companies (Cognition Therapeutics, Voyager Therapeutics, MindImmune, Cognito Therapeutics) and two indications (Dementia with Lewy Bodies, Alzheimer's Disease). Payer and market access analysis is outside the scope of this edition.

References

[1] "Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis." Cognition Therapeutics, Inc. / SEC EDGAR EX-99.1, March 2, 2026. Link

[2] "Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results." Voyager Therapeutics, Inc. / GlobeNewswire, March 9, 2026. Link

[3] "MindImmune Secures $5 Million Strategic Investment from the Alzheimer's Drug Discovery Foundation to Pioneer Immune-Driven Therapies for Alzheimer's Disease." MindImmune / Business Wire, March 10, 2026. Link

[4] "Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris in Alzheimer's Disease." Cognito Therapeutics / Business Wire, March 5, 2026. Link